Clearance of high-risk HPV infection in Chinese women with normal cervical cytology

Abstract

protection resumed cyclic ovarian function, despite the increased follicle-stimulating hormone levels for the first year after chemotherapy [2]. Similarly, cetrorelix might protect the surviving undifferentiated germline stem cells from gonadotoxicity, allowing them to regenerate ovarian follicles and restore regular menses and fertility. Longer follow up is required to estimate the incidence of permanent ovarian failure. Future studies are needed with more patients and adjustment of cetrorelix administration because the dose used in the present study might not achieve full suppression of gonadotropins. A recent pilot study has been conducted involving patients treated with cyclophosphamide for malignancies and autoimmune diseases [4]. Although the study reported similar results, it is not directly comparable with the present study because the patients received significantly lower doses of cetrorelix, for a shorter period and without a control group. In conclusion, administration of 3 mg of cetrorelix every second day in women treated with chemotherapy for hematological malignancies significantly decreased the incidence of secondary amenorrhea, although full protection of ovarian function was not achieved. Conflict of interest